Oral JAK Inhibitors (Xeljanz®/XR, Olumiant®, Rinvoq®) – Updated labeling
December 2, 2021 - The FDA approved a class-wide update to the labeling for the oral JAK inhibitors consistent with the Drug Safety Communication issued on September 1, 2021 by the FDA.
Download PDF
